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Abstract
Purpose We studied the prevalence of medications of questionable benefit in the last 6 months of life among older nursing home
residents with and without dementia in Germany.
Methods A retrospective cohort study was conducted on claims data from 67,328 deceased nursing home residents aged 65+
years who were admitted between 2010 and 2014. We analyzed prescription regimens of medications of questionable benefit in
the 180–91-day period and the 90-day period prior to death for residents with dementia (n = 29,052) and without dementia (n =
38,276). Factors associated with new prescriptions of medications of questionable benefit prior to death were analyzed using
logistic regression models among all nursing home residents and stratified by dementia.
Results A higher proportion of nursing home residents with dementia were prescribed at least one medication of questionable
benefit in the 180–91-day (29.6%) and 90-day (26.8%) periods prior to death, compared with residents without dementia (180–
91 days, 22.8%; 90 days, 20.1%). Lipid-lowering agents were the most commonly prescribed medications. New prescriptions of
medications of questionable benefit were more common among residents with dementia (9.8% vs. 8.7%). When excluding anti-
dementia medication, new prescriptions of these medications were more common among residents without dementia (6.4% vs.
8.0%). The presence of dementia (odds ratio [OR] 1.40, 95% confidence interval [95%CI] 1.32–1.48) and excessive polypharmacy
were associated with new prescriptions of medications of questionable benefit prior to death (OR 4.74, 95%CI 4.15–5.42).
Conclusion Even when accounting for anti-dementia prescriptions, the prevalence of nursing home residents with dementia
receiving medications of questionable benefit is considerable and may require further attention.
Keywords Dementia . Institutionalization . Inappropriate medications . Palliative care . Polypharmacy
Introduction
The estimated prevalence of dementia among people aged
60 years and older is between 5 and 7% [1]. In 2010, around
5.6 million people lived with dementia worldwide, with num-
bers expected to rise to 65.7 million in 2030 [1]. Advanced
dementia is characterized by severe cognitive impairment,
functional decline, and multiple complications like pneumo-
nia and dysphagia [2]. Thus, the progression of dementia often
requires care in a nursing home, where individuals with ad-
vanced dementia often receive medical and palliative care at
the end of life [2–6].
Medications are an important cornerstone in the manage-
ment of dementia. However, a fine balance between harm and
benefit exists, particularly when shifting from disease man-
agement to palliative care, with a focus on improved quality
of life [7]. A majority of patients with dementia are older
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people, who are often burdened by more than one chronic
condition [8, 9]. As such, individuals with dementia are often
exposed to polypharmacy, i.e., a high number of medications.
The risk of drug–drug and drug–disease interactions warrants
cautious prescribing practices and guidelines to decrease the
risk of adverse outcomes [10–12]. When shifting toward pal-
liative care among older people with dementia, the primary
focus becomes the prevention and management of suffering,
comfort, as well as support of caregivers [2, 4]. With regard to
the lack of guidelines in palliative care interventions in nurs-
ing homes and the risk of medication-related adverse events, a
consensus panel has defined a list of medications considered
to be “never appropriate” for older people with advanced de-
mentia [13].
Various studies have shown that the prescription of medi-
cations of questionable benefit decreases in the terminal phase
of nursing home residents with dementia [12, 14–17].
However, these studies also suggest that nursing home resi-
dents with dementia may still receive new prescriptions, in-
cludingmedications of questionable benefit, in the last months
prior to death. Studies have considered the prevalence of these
medications in older people with dementia in palliative care
settings in Sweden, the USA, and other countries [12, 14, 15,
17]. Little is known about the situation in Germany and how
prescription patterns of medications of questionable benefit
compare between nursing home residents with and without
dementia.
Therefore, this study aims to identify the prevalence of
medications of questionable benefit in the last 6 months prior
to death among older nursing home residents with and without
dementia in Germany, in consideration of new prescriptions
and associated factors.
Methods
Study design and sample
This retrospective cohort study of older people admitted to
nursing homes between January 1, 2010, and December 31,
2014, has already been described in previous studies [18, 19].
Claims data of a German statutory health insurance (DAK-
Gesundheit), which has an insured population of 6 million
individuals, were used. The German Long-Term Care
Insurance (Gesetzliche Pflegeversicherung) provided data on
nursing home care, including information on level of care
dependency, ranging from care level 1 (in need of care) to care
level 3 (severe need of care).
Study population
The study population included older people who were insured
for at least 365 days without prior nursing home admission
(n = 67,328). All people aged 65 years and older who, after
nursing home admission, died on or before December 31,
2014, were considered in the final study population [19].
The study population included people with and without
dementia. The presence of dementia was assessed using the
ambulatory diagnosis of at least one relevant ICD code in the
quarter of nursing home admission. In line with previous stud-
ies [20, 21], the following ICD-10 codes were used: F00.x,
F01.x, F02.0, F02.3, F03, G30.x, G31.0, G31.1, G31.82,
G31.9, and R54.
Medications of questionable benefit
Information on medication prescribed was assessed through
the five-level Anatomical Therapeutic and Chemical (ATC)
classification system [22]. A previous study reported some
of the medications prescribed in our study on a list of medi-
cations deemed “never appropriate” for older adults with ad-
vanced dementia [13]. Based on a modified Delphi process, a
panel consisting of geriatricians decided on the medications to
be included on the “never appropriate” l is t (see
Supplementary Table 1.).
Newly prescribed and deprescribed medications of ques-
tionable benefit were defined based on the “never appropriate”
medications defined by Holmes et al. [13], and prescriptions
in the 180–91-day period were compared with those in the 90-
day period prior to death. Newly prescribed was defined as
any medication from one of the “never appropriate” groups
having been prescribed within the 90-day period prior to death
if no medication from these groups was prescribed in the 180-
to 91-day period prior to death. Deprescription was defined in
a similar way by the discontinuation of medications from any
of the “never appropriate” groups in the 90-day period prior to
death.
Baseline characteristics
Age at death, sex, number of medications prescribed, length of
stay in nursing home, and level of nursing care were consid-
ered baseline characteristics.
Age was categorized into the subgroups of 65–74 years,
75–84 years, 85–94 years, and 95 years and older.
The number of medications prescribed considered all med-
ications on the ACT 5th level prescribed to an individual
within 90 days of death. The number of medications pre-
scribed was categorized into the previously described
polypharmacy levels of 0–4 medications, 5–9 medications
(minor polypharmacy), and 10 or more medications (exces-
sive polypharmacy).
The length of stay in nursing home was counted from the
first day of admission and grouped into quartiles.
The level of nursing care provides information on the level
of dependency of those needing support in their activities of
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daily living, e.g., mobility, eating, and personal hygiene, as
well as housekeeping. The three levels (1 to 3) correspond to
the time required for assistance. A nursing care level of 1
represents some need of assistance, while level 3 represents
the severest need of care [23].
Statistical analysis
Baseline characteristics and number ofmedications prescribed
were assessed separately for nursing home residents with and
without dementia and compared using the chi-squared test and
t test. We assessed the frequency and proportion of never
appropriate medications for the 180–91-day period and the
last 90 days prior to death. In another step, we assessed the
frequency and proportion of newly prescribed and
deprescribed medications. The chi-squared test was used to
compare nursing home residents with and without dementia.
In addition, logistic regression was used to analyze the
likelihood of new prescriptions of questionable medications
within 90 days of death by age, sex, level of nursing care,
number of prescribed medications, and length of stay in the
nursing home. Odds ratios (OR) and 95% confidence intervals
(95% CI) were calculated using a fully adjusted model with
baseline characteristics and number of medications prescribed
for all nursing home residents and stratified by dementia
diagnosis.
All statistical analyses were performed using SAS for
Windows version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics
A total of 29,052 (43.1%) of the 67,329 decedent nursing
home residents were diagnosed with dementia. As shown in
Table 1, residents with dementia tended to be older (average
age at death of 86.4 years with dementia and 84.6 without
dementia). Compared with residents without dementia, a
higher proportion of nursing home residents with dementia
had a nursing care level of 3. On average, nursing home res-
idents without dementia were prescribed more medications
than those with dementia (10.1 vs. 8.6). There was a higher
proportion of women in both groups of nursing home
residents.
Prescribed medication of questionable benefit
Table 2 shows the distribution of prescriptions of questionable
medications in the 180–91-day period prior to death and the
90-day period prior to death between nursing home residents
with and without dementia. Prescription of at least one med-
ication of questionable benefit was more common among
nursing home residents with dementia in the 180–91-day pe-
riod prior to death (29.6% vs. 22.8%) as well as in the 90-day
period prior to death (26.8% vs. 20.1%).When excluding anti-
dementia medications, the prescription of medications of
questionable benefit was less common among nursing home
residents with dementia compared with those without demen-
tia. Lipid-lowering agents were the most commonly pre-
scribed medications of questionable benefit in both groups
of nursing home residents. Acetylcholinesterase inhibitors
and memantine were among the most commonly prescribed
medications of questionable benefit for nursing home resi-
dents with dementia.
Newly prescribed medications of questionable
benefit
Table 3 shows the proportion of nursing home residents with
newly prescribed medications of questionable benefit, strati-
fied by dementia status. New prescription of at least one med-
ication of questionable benefit prior to death was more com-
mon among nursing home residents with dementia compared
with residents without dementia (9.8% vs. 8.7%). However,
when excluding anti-dementia medication, new prescriptions
of medication of questionable benefit were more common
among nursing home residents without dementia (6.4% vs.
8.0%). Lipid-lowering agents were the most common newly
prescribed medications of questionable benefit prior to death
in both nursing home residents with dementia (4.4%) and
without dementia (5.1%). Among nursing home residents
with dementia, anti-dementia medications (acetylcholinester-
ase inhibitors (1.9%) and memantine (1.9%)) were the second
most commonly newly prescribed medications.
Table 4 shows the association between different baseline
characteristics and new prescriptions of medications of ques-
tionable benefit prior to death in the total study population and
stratified by dementia status. Individuals with a dementia di-
agnosis were more likely to receive new medications of ques-
tionable benefit in the 90 days prior to death (OR 1.40, 95%CI
1.32–1.48). Excessive polypharmacy increased the risk for
new prescriptions of medication of questionable benefit more
than fourfold among all nursing home residents (OR 4.74,
95%CI 4.15–5.42).
The effects of sex, level of nursing care, and number of
medications prescribed on the risk of new prescription of med-
ication of questionable benefit did not significantly differ be-
tween residents with and without dementia. However, nursing
home residents with dementia aged 85–94 years and 95+
years were significantly less likely to receive prescriptions of
questionable medication than nursing home residents without
dementia (OR 0.74, 95%CI 0.63–0.87; OR 0.44, 95%CI
0.34–0.56). In contrast, nursing home residents without de-
mentia aged 75 to 84 years and aged 85 to 94 years were at
an excessive risk of receiving medications of questionable
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Table 1 Baseline characteristics
of nursing home residents (n =
67,328)





Age at time of death (mean age (SD)) 86.4 ± 6.5 84.6 ± 7.9 < 0.0001
65–74 years 5.5 13.6
75–84 years 28.7 29.5
85–94 years 58.2 49.5
≥ 95 years 7.6 7.3 < 0.0001
Sex
Female 67.8 71.3
Male 32.2 28.7 < 0.0001
Level of nursing care (at death)
None/level 1 22.0 32.6
Level 2 46.4 47.1
Level 3 31.7 20.3 < 0.0001
Number of prescribed medications prior
to death2 (mean number (SD))
8.6 ± 4.0 10.1 ± 4.8 < 0.0001
0–4 14.8 10.5
5–9 47.0 38.2
≥ 10 38.2 51.3 < 0.0001
Length of stay in nursing home
25th percentile 75.0 33.0
50th percentile 250.0 143.0
75th percentile 598.0 488.0 < 0.0001
1 Chi-squared test (categorical data) or t test (continuous data)
2Within 90 days of death
Table 2 Frequency (in percent) of inappropriate drug use in the 180 days and 90 days prior to death among nursing home residents, stratified by
dementia status
Medications of questionable benefit 180–90 days prior to death p value 90 days prior to death p value
With dementia Without dementia With dementia Without dementia
Acetylcholinesterase inhibitors 9.2 1.1 < 0.0001 7.6 1.1 < 0.0001
Memantine 6.1 0.8 < 0.0001 5.5 0.8 < 0.0001
Lipid-lowering agents 12.8 14.1 < 0.0001 11.5 12.1 < 0.05
Cytotoxic chemotherapy 0.0 0.4 < 0.0001 0.0 0.2 < 0.0001
Hormone antagonists 1.2 2.5 < 0.0001 1.1 2.1 < 0.0001
Antiplatelet agents1 4.3 4.6 < 0.05 4.4 4.7 0.056
Leukotriene inhibitors 0.1 0.1 0.103 0.0 0.1 < 0.01
Immunomodulators 0.4 1.1 < 0.0001 0.4 0.9 < 0.0001
Sex hormones 0.8 1.1 < 0.0001 0.6 0.8 < 0.001
≥One medication of questionable benefit 29.6 22.8 < 0.0001 26.8 20.1 < 0.0001
≥One medication of questionable benefit,
excl. anti-dementia medication2
17.7 21.2 < 0.0001 16.4 18.5 < 0.0001
1 Excluding aspirin
2 Excluding acetylcholinesterase inhibitors and memantine
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benefit (OR 1.28, 95%CI 1.14–1.43; OR 1.22, 95%CI 1.10–
1.37).
Deprescribing of medications of questionable benefit
In addition, Table 3 shows that a greater proportion of nursing
home residents with dementia was subject to deprescription of
medications of questionable benefit (13.2% vs. 11.6%). Lipid-
lowering (5.7%) and also anti-dementia medications (acetyl-
cholinesterase inhibitors, 3.5%; memantine, 2.5%) were the
most commonly deprescribed medications of questionable
benefit among nursing home residents with dementia.
Discussion
Main findings
Our longitudinal study among deceased nursing home resi-
dents showed that more than one quarter of the nursing home
residents with dementia received medications of questionable
benefit prior to death. When excluding anti-dementia medica-
tions, a lower proportion of nursing home residents with de-
mentia received medications of questionable benefit than
nursing home residents without dementia. However, more
than 16% of nursing home residents with a dementia diagnosis
still received inappropriate medications, and 6.4% even re-
ceived new prescriptions, i.e., new treatment initiations in
the 90 days prior to death. Of these new prescriptions, lipid-
lowering agents were the most commonly prescribed.
Residents with dementia were at increased risk for new
prescriptions of medications of questionable benefit, even
when age, level of nursing care, number of medications, and
time since nursing home admission were considered.
Comparison with other studies
Our study used the Holmes et al. criteria employed by previ-
ous studies on questionable medication prescriptions in de-
mentia [13–15, 17, 24]. Our results on residents with dementia
are comparable with those of a Swedish study by Morin et al.,
which reported that 32.8% of nursing home residents with
dementia received medications of questionable benefit prior
to death [14]. The study population by Morin et al. had a
higher proportion of residents aged 85+ years (72.4%) than
our population (65.8%). In addition, our study included those
aged 65 to 74 years and considered exclusively nursing home
residents. Another study conducted by Matlow et al. in a
Canadian setting reported up to 86.3% of nursing home resi-
dents with dementia receiving at least one medication of ques-
tionable benefit in the 120-day period prior to death [15].
However, this study included only nursing home residents
already subject to at least one medication of questionable ben-
efit in the last year of life. Similar to Morin et al. and Matlow
et al., we found a decline in the prevalence of medications of
questionable benefit among nursing home residents closer to
death [14, 15].
The most commonly prescribed questionable medications
came from the group of lipid-lowering agents. Yet, the benefit
of lipid-lowering agents in patients with dementia is question-
able. Studies have shown that these medications reduce the
quality of life in terminally ill patients and are safe to
Table 3 Frequency (in percent) of newly prescribed and deprescribed medications of questionable benefit prior to death among nursing home
residents, stratified by dementia status
Medications of questionable benefit Newly prescribed prior to death p value Deprescribed prior to death p value
With dementia Without dementia With dementia Without dementia
Acetylcholinesterase inhibitors 1.9 0.4 < 0.0001 3.5 0.5 < 0.0001
Memantine 1.9 0.3 < 0.0001 2.5 0.3 < 0.0001
Lipid-lowering agents 4.4 5.1 < 0.0001 5.7 7.1 < 0.0001
Cytotoxic chemotherapy 0.0 0.1 < 0.0001 0.0 0.2 < 0.0001
Hormone antagonists 0.4 0.7 < 0.0001 0.4 1.1 < 0.0001
Antiplatelet agents1 1.7 2.0 < 0.001 1.6 2.0 < 0.0001
Leukotriene inhibitors 0.0 0.1 < 0.01 0.0 0.0 0.235
Immunomodulators 0.1 0.4 < 0.0001 0.1 0.6 < 0.0001
Sex hormones 0.3 0.4 0.083 0.5 0.7 < 0.001
≥One medication of questionable benefit 9.8 8.7 < 0.0001 13.2 11.6 < 0.0001
≥One medication of questionable benefit,
excl. anti-dementia medication2
6.4 8.0 < 0.0001 7.9 10.9 < 0.0001
1 Excluding aspirin
2 Excluding acetylcholinesterase inhibitors and memantine
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discontinue [25, 26]. New initiation of these medications,
shown to take place in our study, should therefore be carefully
considered. Lipid-lowering agents are associated with a risk of
adverse effects, and their benefits accrue only after a
prolonged time [25]. Thus, the benefits of lipid-lowering
agents are limited and may not outweigh the impact on quality
of life among older people in palliative care settings [27, 28].
Further research and direct guidelines may be needed to reg-
ulate new lipid-lowering agent prescriptions among nursing
home residents with advanced dementia [29].
Anti-dementia drugs, particularly acetylcholinesterase in-
hibitors, were among the most commonly prescribed medica-
tions of questionable benefit, a finding which is in line with
previous studies [14–16]. Acetylcholinesterase inhibitors are
indicated for mild to moderate dementia in order to attenuate
the manifestation of dementia [30–33]. However, the indica-
tion for acetylcholinesterase inhibitors among nursing home
residents with advanced dementia is less clear, and their use in
this population is considered off label in Germany [33–36].
Despite the questionable benefits, discontinuation of acetyl-
cholinesterase inhibitors may be difficult and requires individ-
ualized approaches [13, 37]. However, our study also showed
that 1.9% of nursing home residents with dementia received a
new acetylcholinesterase inhibitor, i.e., initiation of this med-
ication in the last 90 days prior to death. New prescription of
this medication requires careful consideration given the poten-
tial adverse effects [38], decrease in quality of life [39], and
primary treatment indication for mild to moderate dementia
[32]. For residents with moderate to severe dementia,
memantine is an approved option that can be combined with
acetylcholinesterase inhibitors [40]. However, the clinical
benefits of memantine in advanced dementia are limited, and
its side-effect profile needs to be carefully considered in end-
of-life care [41–43]. In addition to the prevalent prescription
among residents with dementia, anti-dementia medications
were also prescribed among residents without dementia.
Table 4 Adjusted odds ratios and 95% confidence intervals for new prescriptions of medication of questionable benefit by characteristics of nursing
home residents
Characteristics New prescription of medications of questionable benefit
With dementia Without dementia All
Frequency (%) OR (95% CI) Frequency (%) OR (95% CI) Frequency (%) OR (95% CI)
Age at death in groups
65–74 years 207 13.0 REF. 476 9.1 REF. 683 10.0 REF.
75–84 years 1030 12.4 0.98 (0.83–1.15) 1147 10.1 1.28 (1.14–1.43) 2177 11.1 1.21 (1.11–1.33)
85–94 years 1510 8.9 0.74 (0.63–0.87) 1581 8.4 1.22 (1.10–1.37) 3091 8.6 1.04 (0.95–1.14)
≥ 95 years 106 4.8 0.44 (0.34–0.56) 123 4.4 0.75 (0.61–0.92) 229 4.6 0.64 (0.54–0.74)
Sex
Female 1769 9.0 REF. 2196 8.1 REF. 3965 8.4 REF.
Male 1084 11.6 1.20 (1.10–1.30) 1131 10.3 1.30 (1.21–1.41) 2215 10.9 1.26 (1.19–1.33)
Level of nursing care
None/level 1 775 12.2 REF. 1175 9.4 REF. 1950 10.3 REF.
Level 2 1368 10.2 0.84 (0.77–0.93) 1543 8.6 0.89 (0.82–0.96) 2911 9.2 0.87 (0.82–0.92)
Level 3 710 7.7 0.71 (0.64–0.79) 609 7.9 0.88 (0.80–0.97) 1319 7.8 0.79 (0.73–0.85)
Number of prescribed medications prior to death1
0–4 156 3.6 REF. 86 2.1 REF. 242 2.9 REF.
5–9 1048 7.7 2.11 (1.78–2.51) 868 5.9 2.87 (2.30–3.59) 1916 6.8 2.39 (2.08–2.74)
≥ 10 1649 14.9 4.03 (3.40–4.77) 2373 12.1 5.94 (4.77–7.39) 4022 13.1 4.74 (4.15–5.42)
Time at nursing home quartiles
100th (> 541 days) 541 6.6 REF. 551 6.4 REF. 1092 6.5 REF.
75th (190–540 days) 649 8.0 1.11 (0.99–1.25) 632 7.3 1.06 (0.94–1.20) 1281 7.6 1.09 (1.00–1.18)
50th (48–189 days) 903 12.0 1.55 (1.38–1.74) 789 8.6 1.15 (1.03–1.29) 1692 10.1 1.34 (1.23–1.45)
25th (< 47 days) 760 14.8 1.90 (1.68–2.14) 1355 11.5 1.57 (1.41–1.75) 2115 12.5 1.70 (1.57–1.84)
Dementia
No 3327 8.7 REF.
Yes 2853 9.8 1.40 (1.32–1.48)
1Within 90 days prior to death
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This may be related to the treatment of dementia secondary to
other organic causes or isolated treatment of dementia-related
symptoms like memory loss among residents without a formal
dementia diagnosis [44].
Nursing home residents with a dementia diagnosis were
more likely to receive at least one new prescription of ques-
tionable medications prior to death compared with residents
without dementia, which is mainly attributable to the prescrip-
tion of anti-dementia medications. In addition, polypharmacy,
i.e., the concurrent use of 5 or more medications, was strongly
associated with new prescriptions of questionable medication,
while residents of older age and a higher level of nursing care
were less likely to receive such new prescriptions. These re-
sults mirror previous findings and may reflect an earlier and
more targeted initiation of palliative approaches for older and
more morbid nursing home residents [15]. Residents with de-
mentia and polypharmacy, those of younger age, i.e., 65 to
74 years, and those with a low nursing care level were more
likely to be prescribed new medications of questionable ben-
efit. New prescriptions may be related to a lack of guidelines,
misjudgment of disease progression, and difficulties estimat-
ing life expectancy among these residents with advanced de-
mentia [2, 45, 46]. This may lead to varying treatment ap-
proaches, including the initiation of new anti-dementia medi-
cations at the end of life [24, 47, 48]. Studies have pointed to
the use of prognostic models when estimating life expectancy
among individuals with dementia [45, 46, 49]. Assessing the
life expectancy of nursing home residents with advanced de-
mentia can also guide the clinical decision-making process in
prescription regimens. The use of prognostic tools, alongside
advance care planning and in consideration of the nursing
home resident’s preferences, can then assist palliative care
decisions. These decisions may involve a greater focus on
improved comfort and quality of life, including the minimiza-
tion of interventions like tube feeding or medication prescrip-
tions [16, 50–52].
In residents both with and without dementia, men were
more likely to receive new medications of questionable bene-
fit prior to death. A previous study has pointed toward sex-
specific differences in dementia care, with men more com-
monly receiving burdensome interventions at the end of life
[53]. The differences between men and women may be more
related to social contexts than biological phenomena, i.e.,
gender-based differences in the provision of care or different
attitudes toward death [53–55].
Strengths and limitations
One of the major strengths of this study is its sample size. We
were able to assess 67,328 deceased nursing home residents
and their respective medication claims prior to death. In addi-
tion, information obtained from claims data has been shown to
be of high accuracy [56]. To the best of our knowledge, no
previous study reported similar findings in the context of
Germany or considered new prescriptions of these medica-
tions prior to death.
However, there are also limitations to our study that need to
be considered. Information on dementia diagnoses was limit-
ed to the details available in the claims data. Misclassification
of some residents with dementia is possible, with residents
receiving no dementia diagnosis but anti-dementia medica-
tion. In addition, unreported or undiagnosed individuals, par-
ticularly those with mild presentations, may not have been
included, leading to an underestimation of dementia cases
and the use of questionable medications in this group. The
selected sample may primarily reflect nursing home residents
with typical signs and thus advanced levels of dementia.
The utilized list of “never appropriate” medications from
Holmes et al. focuses on individuals with advanced dementia
[13]. We used this list in our assessment of all nursing home
residents, comparing residents with and without dementia pri-
or to death. However, we employed this list with and without
anti-dementia drugs.
The assessed data stem from a single health insurance pro-
vider in Germany. It needs to be considered that German in-
surance funds differ in regard to sex, age, socioeconomic
backgrounds, and morbidity. DAK-Gesundheit covers a rela-
tively high proportion of women as well as individuals with
higher levels of morbidity [57]. These differences need to be
considered regarding the generalizability of data to the total
German population.
Conclusion
This study assessed the prevalence ofmedications of question-
able benefit among nursing home residents with and without
dementia prior to death, showing that more than one-fourth of
nursing home residents with dementia and limited life expec-
tancy received these medications compared with one-fifth of
residents without dementia. The number of nursing home res-
idents with advanced dementia and limited life expectancy
receiving these medications is considerable, even when ac-
counting for anti-dementia medication. Physicians may con-
sider nursing home residents’ life expectancy when prescrib-
ing new medications, particularly those of questionable
benefit.
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